KRAS and non-small cell lung carcinoma: Abemaciclib, a CDK4/6 inhibitor, has been investigated in the JUNIPER trial, a phase III study in KRAS mutated pretreated NSCLC, and it has not improved OS compared to erlotinib, the control arm (7.4 vs 7.8 months, HR 0.968, p=0.77) (106).